stockrowCRISPR Therapeutics AG
CRSP Healthcare Biotechnology
CRISPR Therapeutics AG’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, down 90.6% from fiscal 2024.
- Revenue
- +1,325.1%
- EPS
- +1.55%
- Free cash flow
- −6.36%
Quarter to September 2026, against a year earlier
Follow CRSP
Alert me
CRISPR Therapeutics AG (CRSP) Operating margin
CRISPR Therapeutics AG's operating margin over the twelve months to 30 September 2026 was −2,114.8%, up 16818.9 percentage points from fiscal 2025 (−18,933.7%). Over the past ten years it has ranged from −56,190.4% (fiscal 2022) to 40.8% (fiscal 2021); the current reading is higher than 27% of that period. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Operating margin, annual
Embed this chart
Annual newest first
| Period | Operating margin | Change (points) |
|---|---|---|
| FY2025 | −18,933.7% | (17,683.27) |
| FY2024 | −1,250.4% | (1,190.43) |
| FY2023 | −60.0% | 56,130.45 |
| FY2022 | −56,190.4% | (56,231.22) |
| FY2021 | 40.8% | 49,336.37 |
| FY2020 | −49,295.6% | (49,311.69) |
| FY2019 | 16.1% | 5,103.94 |
| FY2018 | −5,087.8% | (4,930.11) |
| FY2017 | −157.7% | 1,161.64 |
| FY2016 | −1,319.3% | 9,097.27 |
Quarterly newest first
| Period | Operating margin | Change (points) |
|---|---|---|
| Sep 2026 | −1,026.5% | 125.36 |
| Jun 2026 | −1,151.8% | 7,781.49 |
| Mar 2026 | −8,933.3% | 8,979.17 |
| Dec 2025 | −17,912.5% | (3,057.72) |
| 40 more quarters | Free account |
Against its own ten years
Operating margin against peers
| Company | Operating margin |
|---|---|
| COGT Cogent Biosciences, Inc. compare | 0.00% |
| MANE Veradermics Incorporated compare | 0.00% |
| ERAS Erasca, Inc. compare | 0.00% |
| DFTX Definium Therapeutics, Inc. compare | 0.00% |
| EWTX Edgewise Therapeutics, Inc. compare | 0.00% |
| LEGN Legend Biotech Corporation Sponsored ADR compare | −5.06% |
| TVTX Travere Therapeutics, Inc. compare | −20.5% |
| CRSP CRISPR Therapeutics AG | −2,114.8% |
| DNTH Dianthus Therapeutics, Inc. compare | −8,683.9% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Operating margin is
EBIT Margin tells an investor how much operating profit, before interest and taxes, a company keeps from each unit of revenue.
EBIT ÷ Revenue
More on CRSP
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement